XML 15 R6.htm IDEA: XBRL DOCUMENT v3.20.1
STATEMENTS OF CASH FLOWS - USD ($)
12 Months Ended
Feb. 29, 2020
Feb. 28, 2019
CASH FLOWS FROM OPERATING ACTIVITIES    
Net loss $ (1,634,482) $ (1,637,717)
Adjustments to reconcile net loss to net cash used in operating activities:    
FDA clinical trial expenses paid directly by S.R. Burzynski, M.D., Ph.D. 1,138,975 1,081,051
Changes in operating assets and liabilities    
Prepaid expenses 1,774 6,959
Accounts payable (40,260) 59,124
Accrued liabilities 3,880 13,067
NET CASH USED IN OPERATING ACTIVITIES (530,113) (477,516)
CASH FLOWS FROM FINANCING ACTIVITIES    
Cash contribution recorded 529,568 477,718
NET CASH PROVIDED BY FINANCING ACTIVITIES 529,568 477,718
NET INCREASE (DECREASE) IN CASH (545) 202
CASH AT BEGINNING OF YEAR 708 506
CASH AT END OF YEAR $ 163 $ 708